Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Mar 21, 2008; 14(11): 1682-1689
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1682
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1682
Table 1 Expression of estrogen receptors, progesterone receptors and androgen receptors in HCC
Table 2 Randomized clinical trials testing the efficacy of tamoxifen in HCC
| Study characteristics | Enclosed in meta-analysis | ||||||||
| Reference | Patients | Tamoxifen arm | Comparator | Simonetti | Mathurin | Llovet | Cochrane | ||
| Treatment | Overall survival | Treatment | Overall survival | ||||||
| Melia, 1987[22] | 59 | Adriamycin 60 mg/m2 + tam 20 mg/d | Median: 6 wk | Adriamycin 60 mg/m2 | Median: 8 wk | X | X | X | |
| Farinati, 1990[23] | 38 | Tam 30 mg/d | Median: 36 wk | No treatment | Median: 8 wk | X | |||
| Uchino, 1993[24] | 26 | Cisplatin, adriamycin, 5-fluorouracil + Tam 25 mg/m2 per d + MPA 400 mg/m2 per d | 1-yr: 44.5% | Cisplatin, adriamycin, 5-fluorouracil | 1-yr: 33.0% | X | X | ||
| Elba, 1994[25] | 22 | Tam 60 mg/d | Median: 74 wk | Placebo | Median: 52 wk | X | X | X | X |
| Martinez Cerezo, 1994[26] | 36 | Tam 20 mg/d | Median: 261 d | Symptomatic treatment | Median: 172 d | X | X | X | X |
| Castells, 1995[27] | 120 | Tam 20 mg/d | 1-yr: 51% | Placebo | 1-yr: 43% | X | X | X | X |
| Coll, 1995[28] | 61 | Tam 20 mg/d | 1-yr: 24% | Placebo | 1-yr: 25% | X | X | ||
| Manesis, 1995[29] | 85 | Tam 30 mg/d + triptorelin | Median: 282 d | Placebo | Median: 127 d | X | X | X | |
| Flutamide 750 mg/d + triptorelin | Median: 112 d | ||||||||
| Riestra, 1998[30] | 77 | Tam 40 mg/d | 1-yr: 30% | Placebo | 1-yr: 37.8% | X | X | ||
| CLIP group, 1998[31] | 496 | Tam 40 mg/d | Median: 15 mo | No treatment | Median: 16 mo | X | X | ||
| Liu, 2000[18] | 119 | Tam 30 mg/d | Median: 44 d | Placebo | Median: 41 d | X | X | ||
| Chow, 2002[32] | 329 | Tam 60 mg/d | 3 mo: 41% | Placebo | 3-mo: 44% | X | |||
| Tam 120 mg/d | 3 mo: 35% | ||||||||
| Barbare, 2005[33] | 420 | Tam 20 mg/d | Median: 4.8 mo | Symptomatic treatment | Median: 4.0 mo | ||||
- Citation: Maio MD, Daniele B, Pignata S, Gallo C, Maio ED, Morabito A, Piccirillo MC, Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol 2008; 14(11): 1682-1689
- URL: https://www.wjgnet.com/1007-9327/full/v14/i11/1682.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.1682
